Ricardo is Helping to Accelerate Europe’s Transformation to a Climate-resilient Future
27.7.2023 02:05:00 EEST | Business Wire | Press release
Ricardo, a global strategic environmental and engineering consulting company, is leading the EU Mission Implementation Platform for Adaptation to Climate Change (MIP4Adapt), providing support to the European Commission and everyone delivering the EU Mission on Adaptation to Climate Change.
The Mission is focused on supporting European regions and local authorities to accelerate their adaptation to climate change and building climate resilience. This is of vital importance given the fact that the impacts of climate change are already happening, and more regularly – as evidenced by extreme weather events already increasing in magnitude and frequency which are having direct and indirect impacts on our environment, society, and economy. In turn, these impacts may increasingly lead to transnational spill-over effects on international trade, resource competition, regional conflict, migration, and the spread of pests and diseases.
Ricardo’s experts across Europe are working closely with the European Commission in delivering MIP4Adapt – which is the result of a public procurement process - with the work commitment starting in 2023 and running until 2025. MIP4Adapt’s core team also includes experts from: Fresh Thoughts Consulting, Icatalist, the European Federation of Agencies and Regions for Energy and Environment – FEDARENE, and Joanneum Research, as well as experts from across Europe able to deliver technical assistance to the regional and local authorities in all 27 EU Member States.
In leading MIP4Adapt, Ricardo is facilitating the development of a community of practice to promote the exchange of knowledge and experiences and enable regional and local authorities across Europe to strengthen coordination and collaboration around climate adaptation. The community includes the 308 regional and local authorities that are signatories to the Mission Charter, covers approximately 40% of Europe’s land area and population, and is committed to striving towards climate resilience by 2030. In addition, it comprises relevant EU-funded research and innovation projects, the European Commission and other relevant European institutions, national authorities, and Friends of the Mission, including research institutions and businesses.
Through MIP4Adapt, Ricardo is also delivering technical assistance to the regional and local authorities that are Charter signatories. This includes helping them to: develop their climate adaptation plans; identify appropriate climate adaptation demonstration projects; identify and access suitable finance and funding for implementation of their plans and demonstration projects; and stimulate engagement and mobilisation of citizens and stakeholders in climate adaptation.
Richard Smithers, Director of MIP4Adapt and Ricardo’s international lead on climate adaptation said: “Ricardo’s delivery of MIP4Adapt builds upon our support for the European Commission over the last decade regarding development and implementation of the EU Adaptation Strategy. It also draws on Ricardo’s wide-ranging experience of supporting all aspects of climate adaptation planning at all scales in over 40 countries beyond Europe, and on the expertise of our wider team. Through our leadership of MIP4Adapt, our desire is to help to amplify the Mission’s overall impact across mainland Europe, so it is greater than the sum of individual actions.”
Ends
Notes to editors:
About the EU Mission on Adaptation to Climate Change
Further information about the Mission and MIP4Adapt can be found at the Mission Portal, Visit https://climate-adapt.eea.europa.eu/en/mission
About the core team for MIP4Adapt
Ricardo’s core team for MIP4Adapt also includes experts from Fresh Thoughts Consulting (leading access to the best available knowledge, tools and methods in association with the European Environment Agency), Icatalist (leading on stakeholder and citizen engagement), the European Federation of Agencies and Regions for Energy and Environment – FEDARENE (supporting networking between regional and local authorities) and Joanneum Research (fostering links between the EU Mission on Adaptation to Climate Change and the four other EU Missions).
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726541878/en/
Contact information
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom